Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares second interim results that include 100% protection against serious diseases, including hospitalization
Primary efficacy in the second interim analysis shows that COVAXIN is 78% effective after the second dose to prevent COVID-19 in those without prior infectionDemonstrates 70% efficacy against asymp…
